Cytel To Hold Complex Innovative Trial Design Symposium
Product News Oct 18, 2019
Cytel, provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East® Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.
Cytel has hosted the annual Complex Innovative Trial Design Symposium and East Training since 2011 to connect global thought leaders and innovators from the pharmaceutical industry in order to facilitate the exchange of ideas and reveal new insights on the latest developments in adaptive clinical trial designs. The event also plays a key role in guiding the continual evolution of Cytel’s East platform, the industry-standard software for adaptive clinical trial design and analysis. Amongst the list of guest speakers will be leaders from Pfizer, Takeda and Servier, as well as statistical experts from Cytel, Alexion and Axio.
This year’s symposium will focus on overcoming the acute challenges associated with clinical trials for rare diseases, with an emphasis on how innovative, adaptive clinical trial designs can be exploited to maximize trial efficiency, accommodate specialized data requirements and enhance rare disease trial success rates. The latest insights and detailed case studies will be shared through a series of engaging presentations, and participants will also have the opportunity to actively participate in an East training session on day two.
Currently, rare diseases affect around 350 million patients worldwide, with 90% of rare diseases still without an approved therapy. In addition, scarce patient resources and lack of disease knowledge regarding the best endpoints and treatment effect size makes clinical development for new and effective therapeutics for rare diseases especially difficult.
“In order to overcome the myriad of clinical trial pain points presented by rare diseases, we need to think creatively and adopt a knowledge-sharing approach to the clinical development process,” said Yannis Jemiai, Chief Scientific Officer at Cytel. “The symposium will offer a key space to facilitate peer-to-peer exchanges, ideation, and sharing of practical solutions. We are driving forward novel experimental designs and statistical approaches for better clinical outcomes in patients with rare disorders.”
Delegates will have the opportunity to learn about a range of novel methodological advancements in the rare disease trial space, including:
- The use of natural history data in clinical trials for rare diseases
- The PREVENT trial for Neuromyelitis optica spectrum disorder (NMOSD)
- Historical control information borrowing
The in-depth East software training workshop that will take place on day two will guide participants through the extensive range of powerful trial design tools within East, keeping them up to date on the software platform’s latest developments.